Apexbio Technology LLC GZD824 1421783-64-3 10mM (in 1mL DMSO)

Supplier:  Apexbio Technology LLC B14025.1

GZD824 (CAS 1421783-64-3) is an orally bioavailable inhibitor of the Bcr-Abl kinase a fusion protein exhibiting tyrosine kinase activity involved in regulating cell cycle progression and genomic stability GZD824 binds competitively to the ATP-binding site of Abl kinase effectively inhibiting the phosphorylation and activation of both wild-type (WT) and resistant mutant forms (e g T315I E255K G250E Q252H H396P M351T and Y253F) GZD824 demonstrates sub-nanomolar IC50 values and substantially reduces proliferation in Bcr-Abl-expressing Ba/F3 cell models Preclinical studies in mouse xenograft leukemia models show GZD824 suppresses tumor growth highlighting its potential applicability in research into resistance mechanisms and targeted leukemia therapies

Catalog No. 50-000-62060